Literature DB >> 9512177

Application of the ATC/DDD methodology to monitor antibiotic drug use.

S Natsch1, Y A Hekster, R de Jong, E R Heerdink, R M Herings, J W van der Meer.   

Abstract

In order to monitor the use of antibiotics, it is essential to have comprehensive data on drug consumption. The findings of drug utilisation studies can serve to describe the pattern of drug use in a particular population, to detect areas of concern, and to evaluate the impact of interventions taken to influence the use of drugs. In the present study, the Anatomical Therapeutical Chemical Classification/Defined Daily Doses (ATC/DDD) system developed by the World Health Organisation was evaluated. The system measures the amount of drug used independent of package size and sales price, which allows comparisons not only within an institution but also within a region, a country, or even internationally. Obviously, there can be no modifications of this system. To illustrate the method, the pattern of quinolone use in the general population, in long-term care facilities, and within a single institution was analysed. These drugs were widely used in long-term care facilities in the Nijmegen region of the Netherlands, accounting for about 30% of the antibiotics used in these settings, whereas in the general population as well as in the University Hospital Nijmegen, these drugs constitute only about 6% of the total antibiotics used. These differences are large enough to warrant closer analysis of patterns of antibiotic usage in different settings to identify the reasons for the use of quinolones and to identify measures that might be taken to rationalise the prescription of these drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512177     DOI: 10.1007/bf01584358

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  32 in total

Review 1.  The crisis in antibiotic resistance.

Authors:  H C Neu
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

Review 2.  Strategies to improve antibiotic use.

Authors:  C S Bryan
Journal:  Infect Dis Clin North Am       Date:  1989-12       Impact factor: 5.982

3.  Panel III. Intervention: the use of drug utilization review outcomes.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  1991-11       Impact factor: 6.875

Review 4.  Practical strategies for the appropriate use of antimicrobials.

Authors:  B J Guglielmo
Journal:  Pharm World Sci       Date:  1995-07-28

5.  Monitoring of antibiotic use in a primary and tertiary care hospital.

Authors:  M Thomas; S Govil; B V Moses; A Joseph
Journal:  J Clin Epidemiol       Date:  1996-02       Impact factor: 6.437

Review 6.  Improving the quality of antimicrobial drug use can result in cost containment.

Authors:  I C Gyssens; B J Kullberg
Journal:  Pharm World Sci       Date:  1995-09-22

7.  Measurement of drug utilization in Sweden: methodological and clinical implications.

Authors:  U Bergman; F Sjöqvist
Journal:  Acta Med Scand Suppl       Date:  1984

Review 8.  Bacterial resistance to quinolones: mechanisms and clinical importance.

Authors:  J S Wolfson; D C Hooper
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

Review 9.  Bacterial resistance to fluoroquinolones.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

10.  Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.

Authors:  R M Herings; A de Boer; B H Stricker; H G Leufkens; A Porsius
Journal:  Lancet       Date:  1995-05-13       Impact factor: 79.321

View more
  19 in total

1.  An evaluation of quinolone prescribing in a group of acute hospitals: development of an objective measure of usage.

Authors:  C Curtis; R Fitzpatrick; J F Marriott
Journal:  Pharm World Sci       Date:  2002-04

2.  Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci.

Authors:  M Bertin; A Muller; X Bertrand; C Cornette; M Thouverez; D Talon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

3.  Impact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study.

Authors:  Lucas Magedanz; Erci Maria Silliprandi; Rodrigo Pires dos Santos
Journal:  Int J Clin Pharm       Date:  2012-03-01

4.  Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database.

Authors:  Vera Vlahović-Palcevski; Monja Gantumur; Nives Radosević; Goran Palcevski; Robert Vander Stichele
Journal:  Pharm World Sci       Date:  2010-01-27

5.  Association of community antibiotic consumption with clinically active trachoma in rural Ethiopia.

Authors:  Berhan Ayele; Tesfaye Belay; Teshome Gebre; Mulat Zerihun; Abayneh Amere; Yared Assefa; Dereje Habte; Allison R Loh; Nicole E Stoller; Jeremy D Keenan
Journal:  Int Health       Date:  2011-12       Impact factor: 2.473

6.  Outpatient use of systemic antibiotics in croatia.

Authors:  D Stimac; I Vukusić; J Culig
Journal:  Pharm World Sci       Date:  2005-06

7.  Comparison of the cohort selection performance of Australian Medicines Terminology to Anatomical Therapeutic Chemical mappings.

Authors:  Guan N Guo; Jitendra Jonnagaddala; Sanjay Farshid; Vojtech Huser; Christian Reich; Siaw-Teng Liaw
Journal:  J Am Med Inform Assoc       Date:  2019-11-01       Impact factor: 4.497

8.  Quantifying antibiotic use in paediatrics: a proposal for neonatal DDDs.

Authors:  T B Y Liem; E R Heerdink; A C G Egberts; C M A Rademaker
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-18       Impact factor: 3.267

9.  Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units.

Authors:  Arno Muller; Daniel Talon; Alexandre Potier; Evelyne Belle; Gilles Cappelier; Xavier Bertrand
Journal:  Crit Care       Date:  2005-03-31       Impact factor: 9.097

10.  Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes.

Authors:  Werner C Albrich; Dominique L Monnet; Stephan Harbarth
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.